Among these five potentially critical factors, only FoxO6 protein levels also increased significantly with time after Ang‐II treatment, paralleled by raised levels of the indices of cardiac hypertrophy, specifically, myosin heavy chain β (β‐MHC) and atrial natriuretic peptide (ANP) (Figure 1D,E). The gene discussed is FOXO6; the disease is cardiac hypertrophy.